Yatiri Bio Inc.

Yatiri Bio is proud to host it's 2nd quarterly San Diego Proteomics Happy Hour. Our mission is to bring together those that work on all aspects of proteomics for an open and educational discussion. We are honored to have John Yates III, Earnst W. Hahn professor at TSRI, and president of HUPO give a talk titled “How A Single Mutation in CFTR Causes the Systemic Disease Cystic Fibrosis: Interactions, PTMs, And Structure” to stimulate the conversation. Please join us on Thursday July 11th from 4:30-7:30 pm for drinks, appetizers, and a lively talk by using the below link to RSVP to this event. https://lnkd.in/g8gHpr9J Thank you to Thermo Fisher Scientific and FCVC for sponsoring this event.  

Yatiri Bio Inc. has joined NVIDIA Inception , a program that nurtures startups revolutionizing industries with technological advancements. Yatiri Bio approaches oncology with a whole system perspective, incorporating patient data, organoids, proteomics, and machine learning to create models predictive of patient outcomes. Our models create a molecularly defined patient landscape with testable systems embedded within this landscape, revolutionizing drug discovery. Yatiri Bio models are used by the pharmaceutical industry to identify patients sensitive to their therapeutics, increase the likelihood of clinical approval, expand therapeutic markets, and identify novel therapeutic targets with well-defined patient selection criteria. Joining NVIDIA Inception will help Yatiri Bio to optimize and scale our deep learning algorithms that drive our predictive models with access to training and GPU cloud credits.   The program will also offer Yatiri Bio the opportunity to collaborate with industry-leading experts and other AI-driven organizations. Dr. Pilgrim Jackson, CEO of Yatiri Bio stated that “The NVIDIA Inception Program is a game changer that allows us to significantly expand our AI/ML capabilities to develop accurate model systems across multiple indications. The end result is that our technology can bring efficacious therapies to the patients that need them. We are fortunate that such programs are available that can further enhance our product offering.”     NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow. #NVIDIAInception, #NVIDIA, #ai, #YatiriBio,

We are excited to announce that we were selected as 1 of 6 finalists for the San Diego Angel Conference Fund VI. This competition shines a spotlight on innovative San Diego-based companies like ours. Come support and meet our CEO Pilgrim Jackson on Thursday, May 9th as he makes his pitch! #SanDeigoConference #Startups #InnovateSD

We are excited to announce that Michael Kamdar, former CEO and President of Molecular Assemblies, will join Yatiri Bio Inc.’s strategic advisory board. Mike has a very successful track record of helping businesses raise money, scale operations, and cultivate growth. Mike has a long list of accomplishments including having negotiated over $1B in business deals and raised more than $450M from venture firms and public markets. His vast business experience and scientific knowledge are also showcased in the numerous companies that he has led and co-founded. We look forward to working closely with Mike as we raise our Series A financing and fully commercialize our AML platform with pharma partnerships. For more information about this announcement, please see https://lnkd.in/gNbpUxS8

We are excited to learn that Yatiri Bio Inc. was selected as one of 12 semifinalists for the San Diego Angel Conference Fund VI. There were 101 companies that applied for the chance to secure a $200,000 angel investment. We would like to send a big shout out to our talented people. Thank you for your hard work and dedication! #proteomics #sdac #sandiegoangelconference

We look forward to meeting those of you that are at American Society of Hematology and discussing the results of our work.

Yatiri Bio will be attending the 65th annual American Society of Hematology (ASH) meeting in San Diego, CA from December 9 – 12. Yatiri Bio was fortunate to be selected for a poster presentation that highlights the further development of our technology for drug discovery and therapeutic positioning. This platform integrates cutting-edge proteomics with ex vivo drug sensitivity to develop a machine learning model predictive of AML patient outcomes. Our results focus on identifying a novel patient population sensitive to Venetoclax, which is a significant therapy being utilized for the treatment of Acute Myeloid Leukemia (AML). Please stop by our poster (publication number 4338) on Monday, December 11 from 6 – 8 pm at the San Diego Convention Center, Halls G – H. Our work is entitled The Identification of a Novel AML Patient Subset Sensitive to Venetoclax Using Matched Proteomics and Diverse Ex Vivo Models. Dr. Pilgrim Jackson, the CEO of Yatiri Bio, will be there to discuss our accomplishments and how our technology can help you in your quest to bring new therapies to the market faster. #proteomics #aml #ash2023 #ai #Venetoclax #precisionmedicine #machinelearning